Anna Aleskog
Overview
Explore the profile of Anna Aleskog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kaderi M, Murray F, Jansson M, Merup M, Karlsson K, Roos G, et al.
Leuk Res
. 2007 Nov;
32(6):984-7.
PMID: 18006055
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease with no known single predisposing genetic factor shown in all cases. Recently, a single nucleotide polymorphism (SNP) T393C in the GNAS1...
12.
Lindhagen E, Rickardson L, Elliott G, Leoni L, Nygren P, Larsson R, et al.
Invest New Drugs
. 2007 Apr;
25(4):297-303.
PMID: 17440681
SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their cytotoxic activity was further studied herein using a well-characterized human tumour...
13.
Walsh S, Grabowski P, Berglund M, Thunberg U, Thorselius M, Tobin G, et al.
Eur J Haematol
. 2007 Feb;
78(4):283-9.
PMID: 17286609
Telomere length was recently reported to correlate with cellular origin of B-cell malignancies in relation to the germinal center (GC). In this report, we measured telomere length by quantitative-PCR in...
14.
Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson R, et al.
Cancer Chemother Pharmacol
. 2006 Dec;
60(4):545-53.
PMID: 17186240
Objective: SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic leukaemia (CLL). SDX-308 and SDX-309 are more potent, structurally related...
15.
Olsson-Stromberg U, Aleskog A, Bjornberg A, Hoglund M, Simonsson B, Bengtsson M, et al.
Anticancer Drugs
. 2006 Aug;
17(6):631-9.
PMID: 16917208
The aims of this study were to evaluate the feasibility of using the non-clonogenic fluorometric microculture cytotoxicity assay in drug sensitivity testing of tumor cells from patients with chronic myeloid...
16.
Aleskog A, Hoglund M, Pettersson J, Hermansson M, Larsson R, Lindhagen E
Leuk Res
. 2005 Jul;
29(9):1079-81.
PMID: 16038735
The correlation between drug sensitivity in vitro and the mutation status of the FLT3 receptor gene was evaluated in tumour cells from 17 previously untreated AML patients. Tumour cells with...
17.
Hallbook H, Barbany G, Aleskog A, Bjornberg A, Larsson R, Sundstrom C, et al.
Anticancer Drugs
. 2005 Jun;
16(6):631-4.
PMID: 15930891
We evaluated the in vitro activity of imatinib on BCR-ABL-positive and -negative tumor cells from patients with adult acute lymphoblastic leukemia (ALL), and investigated in vitro interactions between imatinib and...
18.
Tobin G, Thunberg U, Laurell A, Karlsson K, Aleskog A, Willander K, et al.
Haematologica
. 2005 Apr;
90(4):465-9.
PMID: 15820941
Background And Objectives: The immunoglobulin VH gene mutation status is a strong prognostic indicator in B-cell chronic lymphocytic leukemia (CLL), since unmutated VH genes are correlated with short survival. However,...
19.
Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, et al.
Blood
. 2005 Mar;
105(12):4807-12.
PMID: 15746080
B-cell chronic lymphocytic leukemia (CLL) consists of 2 prognostic entities where cases with mutated immunoglobulin V(H) genes have better outcome than unmutated cases. V(H)-mutated CLLs display longer telomeres compared with...
20.
Aleskog A, Larsson R, Hoglund M, Kristensen J, Nygren P, Lindhagen E
Anticancer Drugs
. 2005 Feb;
16(3):277-83.
PMID: 15711179
The aim of the study was to evaluate cellular drug resistance in B cell chronic lymphocytic leukemia (B-CLL) in vitro, and compare it with that in acute myelocytic leukemia (AML)...